Yamamoto, H., Nishi, S., Tomo, T., Masakane, I., Saito, K., Nangaku, M., Hattori, M., Suzuki, T., Morita, S., Ashida, A., Ito, Y., Kuragano, T., Komatsu, Y., Sakai, K., Tsubakihara, Y., Tsuruya K., Hayashi, T., Hirakata, H. and Honda, H. (2017) 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. Renal Replacement Therapy, 3, 36.
https://doi.org/10.1186/s41100-017-0114-y

has been cited by the following article:

• TITLE: Iron Indices and Mortality in Maintenance Hemodialysis Patients

  AUTHORS: Saeko Kumon, Yoichiro Tanaka, Kazuo Kimura, Takako Onuki, Shigeru Otsubo, Kosaku Nitta

  KEYWORDS: Anemia, Ferritin, Hemodialysis, Mortality

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.9 No.5, May 22, 2018

  ABSTRACT: Background: The relationship between the iron indices and mortality in maintenance hemodialysis (MHD) patients has remained unclear. We performed a retrospective, observational cohort study to investigate the relationships between serum ferritin levels and mortality in MHD patients. Methods: MHD outpatients (n = 150) were followed up for a median period of 49 months. Their ESA and low-dose iron supplement dosages were adjusted to maintain their hemoglobin (Hb) concentrations in the 10 - 11 g/dl range in accordance with Japanese guidelines. The Kaplan-Meier method, log-rank tests, and Cox proportional hazards models were used to perform the statistical analyses. The patients were divided into 3 groups according to their serum ferritin levels: a serum ferritin 100 ng/ml group. Results: During the median follow-up period of 49 months, there were 55 deaths. The multivariate analysis showed no significant associations between the ferritin level groups and all-cause mortality or cardiovascular (CV) events, and the Kaplan-Meier analysis showed no significant differences among the 3 ferritin level groups in all-cause mortality and CV event rates. However, the multivariate analysis revealed that age, CRP level and a history of previous CV disease were independently associated with all-cause mortality, while diabetes, previous CV disease, and iron administration were independently associated with CV events. Conclusion: The results of this study revealed no significant associations of MHD patients between the ferritin ranges and all-cause mortality or CV events. Thus, the adverse clinical outcomes in these patients were independently associated with other markers and not with their serum ferritin levels.